Product Specifications
| Purity | ≥98% |
| Molecular Weight | 3367.9 g/mol |
| CAS Number | 863288-34-0 |
| Molecular Formula | C₁₅₂H₂₅₂N₄₄O₄₂ |
| Form | Lyophilised powder |
| Storage Temperature | -20°C |
| Shelf Life | 24 months |
CJC-1295 (No DAC) is a synthetic analogue of growth hormone-releasing hormone (GHRH), engineered for enhanced stability and receptor affinity compared to the native peptide. Unlike the DAC (Drug Affinity Complex) variant, CJC-1295 without DAC has a shorter half-life, producing pulsatile growth hormone release that more closely mimics endogenous GH secretion patterns. It is widely used in preclinical research investigating the GH/IGF-1 axis, pituitary function, and anabolic signalling.
CJC-1295 (No DAC) binds to and activates the GHRH receptor (GHRHR) on pituitary somatotroph cells, stimulating the synthesis and pulsatile release of growth hormone. This in turn drives hepatic IGF-1 production, which mediates downstream anabolic and metabolic effects including protein synthesis, lipolysis, and cellular proliferation. The peptide incorporates amino acid substitutions that confer resistance to dipeptidyl peptidase IV (DPP-IV) cleavage, extending its activity relative to native GHRH(1-29).
CJC-1295 (No DAC) is most commonly co-investigated with Ipamorelin for synergistic GH pulse amplification — available as a pre-formulated CJC-1295 (No DAC) + Ipamorelin blend. Also studied alongside GHRP-6 Acetate. For sustained GH release research, see CJC-1295 (With DAC).
This peptide requires reconstitution with Acetic Acid Solution 1% prior to use.
This product is intended for legitimate laboratory and analytical research use only. Not for human use, veterinary use, or consumer use. Not for diagnostic or therapeutic purposes.
| Purity | ≥98% |
| Molecular Weight | 3367.9 g/mol |
| CAS Number | 863288-34-0 |
| Molecular Formula | C₁₅₂H₂₅₂N₄₄O₄₂ |
| Form | Lyophilised powder |
| Storage Temperature | -20°C |
| Shelf Life | 24 months |